Fiche publication
Date publication
février 2021
Journal
Seminars in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
,
Dr LAMBERT Aurélien
Tous les auteurs :
Lambert A, Conroy T, Ducreux M
Lien Pubmed
Résumé
Pancreatic cancer is still one of the most lethal cancers with a reported 5-year relative survival rate of approximatively 9% and medical treatment remains a major challenge. Systemic treatment is recommended in every setting: resectable, borderline resectable, locally advanced and metastatic. Yet, few groundbreaking changes in practice have occurred in the last 30 years compared to other cancers and new treatments options are highly desirable. Most treatment approaches using chemotherapy have failed to improve patients' life expectancy and the few therapies finally found to have statistically significant benefit actually have modest clinical impact. It is becoming imperative to find new paths for improvement, such as encapsulated agents, new generation targeted therapies and treatments directed against the tumor microenvironment. We report here the new drugs of interest in pancreatic cancer and analyze the most recent failures.
Mots clés
Future direction, Microenvironment, Pancreatic cancer, Precision medicine, Stroma, Targeted therapies
Référence
Semin Oncol. 2021 Feb 23;:
